Remogliflozin Attenuates Thioacetamide-Induced Nephrotoxicity: Association with Nrf2/HO-1, SIRT1/AMPK, and TLR4/NF-κB Pathway Modulation.
Thioacetamide (TAA) induces renal injury via oxidative stress and inflammation. Remogliflozin (Remo), an SGLT2 inhibitor, was evaluated for potential renoprotection. Twenty-four male Wistar rats were assigned to control, TAA (100 mg/kg IP twice weekly), TAA + Remo 25 mg/kg, or TAA + Remo 50 mg/kg (oral daily). Outcomes...